| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3908636 | The Breast | 2012 | 7 Pages |
Abstract
Sunitinib plus docetaxel on Schedule 2/1 did not result in any clinically significant drug-drug interactions. This combination was manageable and exhibited antitumor activity.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jonas Bergh, Gabriella Mariani, Fatima Cardoso, Annelie Liljegren, Ahmad Awada, Lucia Viganò, Xin Huang, Lev Verkh, Kenneth A. Kern, Carla Giorgetti, Luca Gianni,